Gemcitabine+Cisplatin

DRUG3 trials

Sponsors

Boehringer Ingelheim, AstraZeneca, SUNHO（China）BioPharmaceutical CO., Ltd.

Conditions

AdenocarcinomaCarcinoma, Non-Small-Cell LungHER2 Gene MutationNon-small Cell Lung Cancer NSCLC

Phase 1

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

RecruitingNCT05991518

SUNHO（China）BioPharmaceutical CO., Ltd.HER2 Gene Mutation

Start: 2023-04-25End: 2025-12-31Target: 136Updated: 2024-02-20

Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruitingNCT03775486

AstraZenecaNon-small Cell Lung Cancer NSCLC

Start: 2018-12-21End: 2026-09-27Updated: 2026-02-10

Phase 3

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

CompletedNCT01121393

Boehringer IngelheimAdenocarcinoma, Carcinoma, Non-Small-Cell Lung

Start: 2010-04-19End: 2017-11-26Updated: 2018-12-14

Related Papers

A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study

Frontiers in Immunology2024-11-292 citations

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.

2023-06-298 citations

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.

2022-08-1136 citations

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2019-05-204 citations

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring <i>EGFR</i> mutations: subgroup analysis of the LUX-Lung 6 trial.

2018-11-3021 citations

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

2015-06-04759 citations

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

2015-01-121189 citations

Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).

Journal of Clinical Oncology2014-05-2072 citations

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

2014-01-151579 citations